Pediatric and Adolescent Endocrinology

MON-202 - Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed with Central Precocious Puberty in China: A Real-World Retrospective Study

Monday, June 15, 2026

9:00 AM - 2:00 PM CT

Location: ENDOExpo; Poster Floor

Co-Author(s)

LH

Ling Hou, n/a

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China (People's Republic)
XF

Xin Fan, n/a

The Second Affiliated Hospital of Guangxi Medical University
Nanning, China (People's Republic)
RZ

Rongxiu Zheng, n/a

General Hospital, Tianjin Medical University
Tianjin, China (People's Republic)
Yan Sun, Doctoral Degree

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan City, China
XH

Xiaoyan Huang, n/a

Hainan Women and Children’s Medical Center
Haikou, China (People's Republic)
YC

Yiling Cui, n/a

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, China (People's Republic)
CL

Chuan Li, n/a

The Second Affiliated Hospital of Guangxi Medical University
Nanning, China (People's Republic)
PB

Pengli Bao, n/a

General Hospital, Tianjin Medical University
Tianjin, China (People's Republic)
Jianmei Yang, PhD, MD

professor
Shandong provincial hospital
Jinan, China (People's Republic)
GL

Guimei Li, n/a

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, China (People's Republic)
QW

Qian Wang, n/a

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, China (People's Republic)
YC

Yuhua Cai, n/a

Hainan Women and Children’s Medical Center
Haikou, China (People's Republic)
HL

Hailing Luo, n/a

Hainan Women and Children’s Medical Center
Haikou, China (People's Republic)
ZG

Ziheng Guo, n/a

Takeda (China) International Trading Co., Ltd
Shanghai, China (People's Republic)

Abstract Poster Presenter(s)

Xiaoping Luo, MD, PhD

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China

Senior Author/Primary Investigator(s)

Xiaoping Luo, MD, PhD

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China

Disclosure(s):

Yan Sun, Doctoral Degree: No financial relationships to disclose

Xiaoping Luo, MD, PhD: Amoytop: Advisory Board (), Grant Recipient (); GenSci: Advisory Board (), Grant Recipient (), Speakers' Bureau (); Ipsen: Advisory Board (), Grant Recipient (); Kyowa Kirin: Advisory Board (), Grant Recipient (); Lumos: Advisory Board (), Grant Recipient (); Medtronic: Advisory Board (), Grant Recipient (); Novo Nordisk: Advisory Board (), Grant Recipient (), Speakers' Bureau (); Sanofi: Advisory Board (), Grant Recipient (); Takeda: Advisory Board (), Grant Recipient (); Visen: Advisory Board (), Grant Recipient ()

Objective:
Real-world data on GnRH agonist (GnRHa) treatment for central precocious puberty (CPP) in Chinese children are limited. This retrospective, real-world study aimed to evaluate the patient characteristics, treatment patterns, and therapeutic effectiveness of GnRHa therapy in this population.

Methods:
This non-interventional study analyzed data from the Chinese CPP Big Data Platform. Patients diagnosed with CPP who received GnRHa treatment between January 2015 and December 2024 were included. The primary endpoint was treatment duration (≥24 vs. < 24 months). Secondary endpoints included baseline characteristics, LH suppression rate, and treatment-emergent adverse events (TEAEs). Additional outcomes included age at diagnosis, sex distribution, treatment patterns, hormonal profiles (basal estradiol/testosterone, peak LH/FSH), Tanner staging, changes in laboratory tests and BMI, menstrual status, and growth patterns. Analyses were performed using SAS 9.4+, with subgroup analyses by age (≤8 vs. >8years), sex, weight (≤40 vs. >40kg), and GnRHa type.

Results:
Among the FAS population (n=1,477; 94.7% female; mean age, 8.43±1.39years), 80.1% received leuprorelin (37.1% originator leuprorelin, 43.0% generic leuprorelin) and 19.9% received triptorelin. Treatment was predominantly administered every 4 weeks (86.4%) at a mean dose of 121.44 ± 29.34 μg/kg. The mean treatment duration was 19.5±6.85 months, with 38.5% treated for ≥24 months. In the originator leuprorelin subgroup, LH suppression (peak LH ≤ 3mIU/mL) was achieved in >88% of patients at Months 3, 6, and 24. Tanner stage stability (≥85% with no progression/regression) was maintained through 24 months. A general upward trend was observed in mean height and BMI without growth arrest, while BA/AC ratio decreased progressively from 1.24 at baseline to 1.12 at Month 24. The mean estradiol and testosterone levels fluctuated during follow-up, increasing by 7.22 pg/mL and 0.69 ng/mL from baseline at Month 24, respectively. Growth velocity decreased by 2.91 cm/year at Month 24 compared to Month 3. Final height data, available for a female subgroup(n=33) treated with originator leuprorelin, revealed a mean final height of 162.47 cm, significantly exceeding target height (+4.19 cm, p< 0.001) and baseline predicted adult height (+7.60 cm, p < 0.001). TEAEs were rare (0.1%, one case in each subgroup of injection site abscesses), with no serious treatment-related adverse events reported. Post-treatment, 86.4% of female patients resumed regular menstruation.

Conclusions:
GnRHa therapy is effective and well tolerated in Chinese CPP patients. Notably, originator leuprorelin treatment was associated with significant improvement in final height and normalized growth patterns.

Funding: This study was funded by Takeda (China) International Trading Co., Ltd., an affiliation of Takeda Pharmaceutical Company.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*